Interactions between PPAR-α and inflammation-related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis Project.
暂无分享,去创建一个
P. Deloukas | K. Morgan | K. Brown | A. Smith | P. Kehoe | C. V. van Duijn | M. Breteler | O. Combarros | I. Mateo | V. Álvarez | Naomi Hammond | C. Ibrahim-Verbaas | D. Lehmann | D. Warden | E. Coto | H. Kölsch | Y. Aulchenko | G. Wilcock | O. Belbin | C. Duijn | R. Heun | M. Cortina-Borja | M. Schuur | R. Barber | Michael G. Lehmann | C. V. van Duijn | Mario Cortina-Borja | Gordon K. Wilcock | Reinhard Heun | Onofre Combarros | Olivia Belbin | Mario Cortina-Borja | Naomi Hammond
[1] P. Deloukas,et al. Interaction of insulin and PPAR-α genes in Alzheimer’s disease: the Epistasis Project , 2012, Journal of Neural Transmission.
[2] L. Polito,et al. Interleukin-1α, interleukin-1β and tumor necrosis factor-α genetic variants and risk of dementia in the very old: evidence from the “Monzino 80-plus” prospective study , 2012, AGE.
[3] S. Allan,et al. Assessing the contribution of inflammation in models of Alzheimer's disease. , 2011, Biochemical Society transactions.
[4] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[5] J Zhang,et al. The −1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: A meta-analysis , 2011, Journal of the Neurological Sciences.
[6] Nick C Fox,et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.
[7] P. Bertolucci,et al. Interleukin-8-251T > A, Interleukin-1α-889C > T and Apolipoprotein E polymorphisms in Alzheimer’s disease , 2010, Genetics and molecular biology.
[8] N. Herrmann,et al. A Meta-Analysis of Cytokines in Alzheimer's Disease , 2010, Biological Psychiatry.
[9] P. Deloukas,et al. The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project , 2010, BMC Medical Genetics.
[10] Seth Love,et al. Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease , 2010, PloS one.
[11] Mario Cortina-Borja,et al. Open Access Journal of Neuroinflammation Replication by the Epistasis Project of the Interaction between the Genes for Il-6 and Il-10 in the Risk of Alzheimer's Disease , 2022 .
[12] Xiao-dan Jiang,et al. Genetic Analysis of Interleukin-1A C(-889)T Polymorphism with Alzheimer Disease , 2009, Cellular and Molecular Neurobiology.
[13] F. Sánchez-García,et al. Cytokine IL‐1 beta but not IL‐1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain , 2008, European journal of neurology.
[14] R. Maccioni,et al. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. , 2004, Experimental cell research.
[15] W. Maier,et al. Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer’s disease , 2003, Journal of Neural Transmission.
[16] F. Jessen,et al. Association of an interleukin-1β gene polymorphism at position -511 with Alzheimer's disease , 2003 .
[17] H. Möller,et al. Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease , 2003, European Archives of Psychiatry and Clinical Neuroscience.
[18] G. Landreth,et al. Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor α , 2001, Neurochemistry International.
[19] W. Maier,et al. Gene polymorphisms of interleukin‐1α influence the course of Alzheimer's disease , 2001, Annals of neurology.
[20] W. Oertel,et al. Association of an interleukin 1α polymorphism with Alzheimer’s disease , 2000, Neurology.
[21] Sander Kersten,et al. Roles of PPARs in health and disease , 2000, Nature.
[22] F. Jessen,et al. Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population , 2000, Neuroscience Letters.
[23] W. Wahli,et al. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. , 2000, Mutation research.
[24] M. Franceschi,et al. Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.
[25] G. Landreth,et al. Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists , 2000, The Journal of Neuroscience.
[26] F. Jessen,et al. A genetic variation of the inflammatory cytokine interleukin‐6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease , 1999, Annals of neurology.
[27] R. Skinner,et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis , 1996, Neurobiology of Aging.
[28] P. Mcgeer,et al. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.
[29] X. Chen,et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[31] W. Griffin,et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[32] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[33] Nick C Fox,et al. Common variants at ABCA 7 , MS 4 A 6 A / MS 4 A 4 E , EPHA 1 , CD 33 and CD 2 AP are associated with Alzheimer ’ s disease , 2011 .
[34] Mario Cortina-Borja,et al. The synergy factor: a statistic to measure interactions in complex diseases , 2009, BMC Research Notes.
[35] Journal of Neuroinflammation BioMed Central , 2008 .
[36] J. Wands,et al. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[37] F. Jessen,et al. Association of an interleukin-1beta gene polymorphism at position -511 with Alzheimer's disease. , 2003, International journal of molecular medicine.
[38] G. Landreth,et al. Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. , 2001, Neurochemistry international.
[39] G. Landreth,et al. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[40] S. Paul,et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. , 2000, Neurology.